EGFR R222C

CI-VAR-00003770Explore in graph →ClinVar 1000203 CIViC 3344 rs1785212573

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
EGFR R222C	Cetuximab + PanitumumabSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID9655 Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR R222C showed a dose-dependent … (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
Malignant Neoplasm1
EGFR R222C	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9646 The oncogenic potential of somatic EGFR mutations found in colorectal cancer samples were tested. IL-3 independent growth of Ba/F3 cells was achieved when cells were transduced with EGFR R222C. NIH-3T…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
1000203	Uncertain significance	criteria provided, single submitter	1	EGFR-related lung cancer; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype	germline/somatic	2	Apr 10, 2025	clinvar

Unmapped disease2unmapped disease
EGFR R222C	(functional)	Functional	D	Supports Gain Of Function	2	accepted	EID9333 A moderate throughput platform was used to functionally characterize 1000 somatic cancer variants. The platform found EGFR R222C to be an activating mutation based on in vitro screening in two growth-… (full text at CIViC) PMID 29533785 · Ng et al., 2018 · Open in CIViC	civic
EGFR R222C	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID9638 Ba/F3 cells transfected with EGFR R222C had levels of p-EGFR, p-STAT5, and p-AKT that were similar to known activating mutation L858R and higher than in cells expressing wild-type EGFR. PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic